Antonio Calles, Head of the Lung Cancer Unit at Hospital Ruber Internacional, shared a post on X:
“Neoadjuvant chemotherapy adds nothing to osimertinib in terms of ctDNA clearance or pathological responses in resectable EGFR mutant lung cancer (neoADAURA trial).
In my mind, this somehow conflicts with the results from FLAURA -2 in the metastatic setting, where the addition of chemo to osimertinib improves clinical outcomes. Is because different biology (eg., less clonality in smaller tumors?).”
More posts featuring Lung cancer.